Evidence map›Paper›PMID 37792145›Full record

ArticleImmunologic research2024

Harmonization of ANA testing challenge: quantification strategy to accurately predict end-point titers avoiding serial dilution.

Teresa Carbone, Vito Pafundi, Vito Ciardo, Maria Infantino, Antonella Muscella, Salvatore D'Angelo

Abstract read
PubMed Publisher
In one paragraph

Article in Immunologic research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Teresa CarboneImmunopathology Laboratory, San Carlo Hospital, Potito Petrone St., 85100, Potenza, Italy.ORCID 0000-0003-4463-9175
Vito PafundiImmunopathology Laboratory, San Carlo Hospital, Potito Petrone St., 85100, Potenza, Italy. pafundi62@gmail.com.ORCID 0009-0000-0213-3059
Vito CiardoDepartment of Biological and Environmental Science and Technologies, University of Salento, Lecce, Italy.
Maria InfantinoLaboratorio Immunologia Allergologia, San Giovanni Di Dio Hospital, Firenze, Italy.
Antonella MuscellaDepartment of Biological and Environmental Science and Technologies, University of Salento, Lecce, Italy.
Salvatore D'AngeloIReL - Rheumatology Institute of Lucania - San Carlo Hospital, Potenza, Italy.ORCID 0000-0002-7442-1110

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the advantages of automated systems for antinuclear antibody (ANA) analysis, the prediction of end-point titers avoiding serial dilutions is still in progress. The aims of this study were to set a conversion table providing discriminant ranges of fluorescence signal intensity values (FI) corresponding to the end-point titers and validate this tool in a real-life laboratory setting. Eight hundred ninety-four serum samples were analyzed for ANA using Image Navigator System. In order to classify FI into non-overlapping groups corresponding to conventional end-point titers, statistical discriminant analysis was used. Validation study was performed calculating agreement and error rates between visual readings and conversion table of 1119 routine ANA positive samples. Setting of FI ranges corresponding to the end-point titers for different staining patterns was computed. For samples showing single pattern, the overall agreement between visual readings and conversion table was 98.4% for all titers ranging from 1:160 to 1:2560, of which 68.0% had the same titer and 30.4% were within ± one titer difference. Concordance rates according to ANA patterns were as follows: (1) nuclear 98.4%, of which 67.0% had the same titer and 31.4% ± one titer; (2) cytoplasmic 100%, of which 72.7% had the same titer and 27.3% than ± one titer; (3) mitotic 66.6%, of which 33.3% had more ± one titer. Our study developed a quantification method for autoantibodies titers assessment based on just one single sample dilution instead of traditional serial dilution approach, providing significant advantages in routine laboratory in terms of reduction in hand-on time and harmonization of results.

Indexed as

Antibodies, AntinuclearCytoplasmFluorescent Antibody Technique, IndirectAntibodies, AntinuclearAntinuclear antibodyAutomated systemEnd-point titerFluorescence intensityIndirect immunofluorescence

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.